HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Labs wanted for alt method prevalidation

This article was originally published in The Rose Sheet

Executive Summary

Institute for Health and Consumer Protection and the European Center for the Validation of Alternative Methods issue a formal request seeking laboratories to participate in prevalidation of three alternative, non-animal methods for skin sensitization testing, assessing reproducibility and preliminary predictive capacity, according to a recent notice. The three alternative strategies are the Direct Peptide Reactivity Assay, the Myeloid U937 Skin Sensitization Test and the Human Cell Line Activation Test. Selected labs will work in close contact with multinational companies and the European Commission Joint Research Center, "test[ing] coded chemicals by adhering to a defined protocol/procedure." The scientific committee of ECVAM has endorsed a number of non-animal tests already, including EpiSkin, a reconstituted human skin model that is a replacement for the rabbit skin irritation test (1"The Rose Sheet" May 7, 2007)

You may also be interested in...



ECVAM Validates Non-Animal Test Methods For Assessing Cosmetics Safety

The scientific committee of the European Center for the Validation of Alternative Methods has endorsed new safety test methods that reduce or eliminate the use of animals, the European Cosmetic Toiletry and Perfumery Association states in a May 2 release

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel